Laurus Labs Limited

NSEI:LAURUSLABS 株式レポート

時価総額：₹750.8b

Laurus Labs 将来の成長

Future 基準チェック /36

Laurus Labs利益と収益がそれぞれ年間18.8%と13.5%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に18.7% 18.1%なると予測されています。

主要情報

18.8%

収益成長率

18.07%

EPS成長率

Pharmaceuticals 収益成長16.0%
収益成長率13.5%
将来の株主資本利益率18.73%
アナリストカバレッジ

Good

最終更新日05 Jun 2026

今後の成長に関する最新情報

分析記事 • Jan 28

Results: Laurus Labs Limited Beat Earnings Expectations And Analysts Now Have New Forecasts

Laurus Labs Limited ( NSE:LAURUSLABS ) just released its quarterly report and things are looking bullish. It was...

Recent updates

ナラティブの更新 • Jun 03

LAURUSLABS: Future Returns Will Depend On Sustained Confidence In Higher P E Multiples

Analysts have lifted their fair value estimate for Laurus Labs stock to ₹1,044 from ₹913, reflecting updated assumptions around modestly higher revenue growth, improved profit margins and revised future P/E expectations. Analyst Commentary Bullish Takeaways Bullish analysts see the higher fair value estimate as consistent with updated assumptions for Laurus Labs, where modestly higher revenue expectations support a richer long term P/E framework.
ナラティブの更新 • Apr 30

LAURUSLABS: Upcoming Dividend Decision And Stable Assumptions Will Support Future Upside

Analysts have kept the Laurus Labs fair value estimate unchanged at ₹1,270, with small tweaks to revenue growth, profit margin and P/E assumptions. These reflect updated models rather than a shift in overall conviction.
ナラティブの更新 • Apr 15

LAURUSLABS: Stronger Fundamentals And Upcoming Board Decisions Will Support Upside

Analysts have slightly reduced the Laurus Labs fair value estimate to ₹1,270 from ₹1,280 after updating assumptions on revenue growth, margins, and future P/E, while keeping the overall risk profile unchanged. Analyst Commentary Recent Street research on a different company, Laureate Education, still gives you a sense of how bullish analysts may think when they see improving fundamentals, supportive macro factors, or cleaner execution.
ナラティブの更新 • Apr 01

LAURUSLABS: Currency And Execution Uncertainties Will Likely Cap Margin Upside

Analysts have made a small upward tweak to the Laurus Labs fair value estimate, with the price target moving from ₹540.28 to ₹543.09. This reflects updated assumptions on revenue growth and profitability.
ナラティブの更新 • Mar 18

LAURUSLABS: Higher Margin Assumptions Will Likely Struggle Against Execution Risks

Narrative Update on Laurus Labs The updated analyst price target for Laurus Labs moves from about ₹330 to roughly ₹540. Analysts point to revised assumptions for margins and future P/E, along with broadly steady growth expectations, as key drivers of the change.
ナラティブの更新 • Mar 04

LAURUSLABS: Steady Fair Value And Solid Fundamentals Will Support Upside

Analysts have kept their price target for Laurus Labs steady at ₹1,280, reflecting small adjustments to assumptions on discount rate, revenue growth, profit margin and future P/E. These changes are consistent with recent Street research, where targets shifted within a relatively tight range and analysts cited solid fundamentals alongside mixed near term signals.
ナラティブの更新 • Feb 18

LAURUSLABS: Future Returns Will Rely On Confidence In Elevated P E Assumptions

Narrative Update: Laurus Labs Analyst Price Target Analysts have maintained their Laurus Labs price target at ₹913.47, citing largely unchanged assumptions around revenue, profit margins, discount rate, and forward P/E as the basis for keeping fair value steady. Analyst Commentary Analysts covering Laurus Labs are using a similar playbook to recent work on other education and healthcare names, where price targets are adjusted mainly on valuation inputs rather than big changes in growth assumptions.
ナラティブの更新 • Feb 03

LAURUSLABS: Future Returns Will Depend On Confidence In Rich P E Assumptions

Analysts have lifted their fair value estimate for Laurus Labs from ₹863.13 to ₹913.47, citing slightly higher assumptions for revenue growth, profit margins and future P/E multiples, consistent with recent upward target revisions seen in related Street research. Analyst Commentary Bullish analysts point to the higher fair value estimate of ₹913.47 as support for a more constructive view on Laurus Labs, even though inputs are only slightly adjusted.
分析記事 • Jan 28

Results: Laurus Labs Limited Beat Earnings Expectations And Analysts Now Have New Forecasts

Laurus Labs Limited ( NSE:LAURUSLABS ) just released its quarterly report and things are looking bullish. It was...
分析記事 • Jan 25

Laurus Labs Limited's (NSE:LAURUSLABS) Popularity With Investors Is Under Threat From Overpricing

With a price-to-earnings (or "P/E") ratio of 65.1x Laurus Labs Limited ( NSE:LAURUSLABS ) may be sending very bearish...
ナラティブの更新 • Jan 20

LAURUSLABS: Future Returns Will Depend On Rich P E Assumptions Holding

Analysts have lifted their price target for Laurus Labs to ₹863 from about ₹822, reflecting updated assumptions on fair value, profit margins, and future P/E multiples. Analyst Commentary Bullish Takeaways Bullish analysts view the higher price target as a sign that current assumptions on Laurus Labs' fair value leave room for upside if the company executes consistently on profitability.
ナラティブの更新 • Jan 06

LAURUSLABS: Interim Dividend And Higher P E Multiple Will Support Upside

Analysts have raised their price target on Laurus Labs from ₹1,025 to ₹1,280, citing updated assumptions for revenue growth, profit margins, and a higher future P/E multiple. What's in the News The Board of Directors approved an interim dividend of ₹0.80 per equity share of face value ₹2 for the 2025-26 financial year at the meeting held on October 23, 2025 (company filing).
ナラティブの更新 • Dec 21

LAURUSLABS: Interim Dividend May Not Offset Softer Margins Ahead

Analysts have moderately raised their price target on Laurus Labs from ₹303.09 to ₹330.21, citing a slightly higher justified valuation multiple that more than offsets their marginally softer assumptions on revenue growth and profit margins. What's in the News The Board approved an interim dividend of INR 0.80 per equity share (40 percent of the face value of INR 2) for FY 2025-26, signaling confidence in cash flows and shareholder returns (company filing).
ナラティブの更新 • Dec 07

LAURUSLABS: Future Returns Will Likely Hinge On Managing Execution Risks

Analysts have modestly increased their price target for Laurus Labs while maintaining fair value at ₹821.93, citing expectations of sustained earnings growth supported by a solid balance sheet, margin expansion, and revenue momentum from new market opportunities. Analyst Commentary Street research on comparable growth stories in the education and healthcare sectors highlights themes that are directly relevant for Laurus Labs, particularly around how markets price in multi year earnings expansion, balance sheet strength, and scalability in new markets.
ナラティブの更新 • Nov 23

LAURUSLABS: Future Revenue Upside May Be Limited By Execution Risks

Analysts have raised their price target for Laurus Labs slightly, from ₹815.86 to ₹821.93. They cite expectations of stronger revenue growth supported by a robust balance sheet and expanding opportunities in new markets.
ナラティブの更新 • Nov 04

LAURUSLABS: Margin Pressures From Rising Input Costs Will Weigh On Earnings

Analysts have raised their fair value price target for Laurus Labs from ₹724.14 to ₹815.86. They cite increased profitability outlook and sustained margin growth as key drivers for the revision.
分析記事 • Oct 30

Laurus Labs' (NSE:LAURUSLABS) Dividend Will Be ₹0.80

Laurus Labs Limited ( NSE:LAURUSLABS ) will pay a dividend of ₹0.80 on the 22nd of November. Even though the dividend...
ナラティブの更新 • Oct 21

Analysts Cite Growth Momentum and Strong Balance Sheet in Raising Laurus Labs Valuation Estimates

Analysts have raised their fair value estimate for Laurus Labs from ₹694.85 to ₹724.14. They cite continued revenue growth momentum and a strong balance sheet as key drivers for this upward revision.
分析記事 • Oct 19

With Laurus Labs Limited (NSE:LAURUSLABS) It Looks Like You'll Get What You Pay For

Laurus Labs Limited's ( NSE:LAURUSLABS ) price-to-sales (or "P/S") ratio of 8.2x may look like a poor investment...
分析記事 • Aug 31

Laurus Labs (NSE:LAURUSLABS) Seems To Use Debt Quite Sensibly

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
分析記事 • Jul 20

Revenues Tell The Story For Laurus Labs Limited (NSE:LAURUSLABS) As Its Stock Soars 28%

The Laurus Labs Limited ( NSE:LAURUSLABS ) share price has done very well over the last month, posting an excellent...
User avatar
新しいナラティブ • Jan 26

CDMO Expansion May Impact Near-Term Margins But Pave Way For Future Revenue Streams

Heavy investment in CDMO and microbial precision initiatives may lead to revenue delays and short-term margin compression due to underutilized assets.

業績と収益の成長予測

NSEI:LAURUSLABS - アナリストの将来予測と過去の財務データ ( )INR Millions
日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数
3/31/2029102,62115,8046,08816,6696
3/31/202890,76913,4853,69515,72413
3/31/202778,83411,0741,23413,90512
3/31/202668,1298,8885,53616,235N/A
12/31/202567,2168,433N/AN/AN/A
9/30/202563,5846,8407,69616,375N/A
6/30/202559,2865,088N/AN/AN/A
3/31/202555,5403,583-3936,017N/A
12/31/202452,7332,003N/AN/AN/A
9/30/202450,5321,311-3,2772,489N/A
6/30/202450,5401,482N/AN/AN/A
3/31/202450,4081,606-1266,657N/A
12/31/202349,8211,879N/AN/AN/A
9/30/202353,3203,6782,87012,248N/A
6/30/202356,8345,637N/AN/AN/A
3/31/202360,4067,901379,939N/A
12/31/202260,8459,176N/AN/AN/A
9/30/202255,6848,683138,393N/A
6/30/202251,9608,374N/AN/AN/A
3/31/202249,3568,2753439,111N/A
12/31/202149,2278,937N/AN/AN/A
9/30/202151,82310,128-1,7057,112N/A
6/30/202151,17710,532N/AN/AN/A
3/31/202148,1359,8364427,330N/A
12/31/202042,4077,971N/AN/AN/A
9/30/202036,8195,9771,5485,427N/A
6/30/202032,5554,120N/AN/AN/A
3/31/202028,3172,5531,2523,474N/A
12/31/201926,2771,883N/AN/AN/A
9/30/201924,2761,326N/A3,538N/A
6/30/201923,035923N/AN/AN/A
3/31/201922,919938N/A2,977N/A
12/31/201822,170957N/AN/AN/A
9/30/201821,6651,127N/AN/AN/A
6/30/201821,1681,453N/AN/AN/A
3/31/201820,5621,676N/A3,425N/A
12/31/201719,6871,917N/AN/AN/A
9/30/201719,9542,019N/AN/AN/A
6/30/201719,7332,014N/AN/AN/A
3/31/201719,0461,881N/A3,320N/A
3/31/201617,7761,337N/A1,820N/A

アナリストによる今後の成長予測

収入対貯蓄率: LAURUSLABSの予測収益成長率 (年間18.8% ) は 貯蓄率 ( 6.9% ) を上回っています。

収益対市場: LAURUSLABSの収益 ( 18.8% ) はIndian市場 ( 16.1% ) よりも速いペースで成長すると予測されています。

高成長収益: LAURUSLABSの収益は増加すると予測されていますが、大幅には増加しません。

収益対市場: LAURUSLABSの収益 ( 13.5% ) Indian市場 ( 10.8% ) よりも速いペースで成長すると予測されています。

高い収益成長: LAURUSLABSの収益 ( 13.5% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: LAURUSLABSの 自己資本利益率 は、3年後には低くなると予測されています ( 18.7 %)。

成長企業の発掘

7D

1Y

7D

1Y

7D

1Y

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/06/11 02:51
終値2026/06/11 00:00
収益2026/03/31
年間収益2026/03/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Laurus Labs Limited 13 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。22

アナリスト機関
Rohit Bhat360 ONE Capital Market Private Limited
Ashwin MehtaAmbit Capital
null nullAntique Stockbroking Ltd.